The purpose of this study was to evaluate predictors of appropriate therapy in patients with implantable cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death. A retrospective cohort of 321 patients with systolic heart failure undergoing ICD placement for primary prevention of sudden cardiac death was queried with a mean follow-up period of 2.6 years. Appropriate ICD therapy was defined as therapy delivered for termination of a ventricular tachyarrhythmia. Appropriate ICD therapy was delivered in 142 (44%) of the patients. In a multivariate model, body mass index ≥28.8 kg/m2 , chronic kidney disease, left ventricular ejection fraction ≤20% and metabolic syndrome were found to be independent predictors of appropriate ICD therapy. Appropriate ICD therapy was associated with higher cardiovascular mortality. These findings show the importance of identification of risk factors, especially metabolic syndrome, in patients following ICD implantation as aggressive treatment of these co-morbidities may decrease appropriate ICD therapy and cardiovascular mortality.
Metabolic syndrome, ICD therapy, chronic kidney disease, systolic heart failure.
Dennis W.X. Zhu, Cardiology 11102H, Regions Hospital, 640 Jackson Street, Saint Paul, MN 55101, USA. E-mail: firstname.lastname@example.org
Share this Article
Related Content In Interventional Cardiology
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
The ACURATE neo™ and neo2™ Valve Systems
Heart International. 2021;15(1):37-41 DOI: https://doi.org/10.17925/HI.2021.15.1.37
Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk groups.1,2 This rapid expansion has been driven by data from randomized trials showing TAVR as […]
Foreword – Heart International. 2020;14(2):66
Welcome to the latest edition of Heart International. I would like to begin by paying tribute to all the victims of the coronavirus pandemic. I know of very few people who have not lost a family member, friend, colleague or a neighbour with COVID-19. Such deaths are not simply statistics, for behind each death is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!